. 2020 Jun 15;455:116370. doi: 10.1016/j.ijms.2020.116370

Table 5a.

SRM transitions for three other classes of HIV-related antiviral drugs in positive-ion mode: non-peptide protein inhibitors (npPIs), integrase inhibitors (INIs), and C–C chemokine receptor type 5 inhibitors (CCR5).

Compound	Class	m/z of [M+H]⁺	Formula	m/z of SRM product-ion	Formula	Literature
Non-peptide protein inhibitors (npPIs)
darunavir	npPI	548.242	[C₂₇H₃₈N₃O₇S]⁺	436.190	[C₂₁H₃₀N₃O₅S]⁺	[22]
				392.200	[C₂₀H₃₀N₃O₃S]⁺	[14,16,18,22,23,54,56]
				156.011	[C₆H₆NO₂S]⁺	[17]
				69.033	[C₄H₅O]⁺	[19]
tipranavir	npPI	603.214	[C₃₁H₃₄F₃N₂O₅S]⁺	411.062	[C₁₈H₁₄F₃N₂O₅S]⁺	[14,16]
				201.082	[C₁₂H₁₀FN₂]⁺ ?	[18]
				172.039	[C₁₀H₆NO₂]⁺	[54]
Integrase inhibitors (INIs)
bictegravir	INI	450.127	[C₂₁H₁₉F₃N₃O₅]⁺	289.082	[C₁₄H₁₃N₂O₅]⁺	[23,89,90]
bictegravir	INI	450.127	[C₂₁H₁₉F₃N₃O₅]⁺	145.026	[C₇H₄F₃]⁺	[90]
cabotegravir	INI	406.121	[C₁₉H₁₈F₂N₃O₅]⁺	263.066	[C₁₂H₁₁N₂O₅]⁺	[91,92]
dolutegravir (DTG)	INI	420.137	[C₂₀H₂₀F₂N₃O₅]⁺	277.082	[C₁₃H₁₃N₂O₅]⁺	[19,22,42,89,93]
				127.052	[C₇H₅F₂]⁺	[19,22,23]
				136.003	[C₆H₂NO₃]⁺	[93]
				126.055	[C₆H₈NO₂]⁺	[42]
elvitegravir	INI	448.132	[C₂₃H₂₄ClFNO₅]⁺	430.122	[C₂₃H₂₂ClFNO₄]⁺	[19,22]
				344.048	[C₁₈H₁₂ClFNO₃]⁺	[18,22,23,42]
				143.006	[C₇H₅ClF]⁺	[42]
raltegravir	INI	445.163	[C₂₀H₂₂FN₆O₅]⁺	361.131	[C₁₇H₁₈FN₄O₄]⁺	[22,42,[40], [55],94]
				109.045	[C₇H₆F]⁺	[16,18,22,23,42,55,94]
				193.077	[C₁₀H₁₀FN₂O]⁺	[55]
C–C chemokine receptor type 5 inhibitors (CCR5)
maraviroc (MVC)	CCR5	514.335	[C₂₉H₄₂F₂N₅O]⁺	389.240	[C₂₃H₃₁F₂N₂O]⁺	[17,55,95]
				280.151	[C₁₆H₂₀F₂NO]⁺	[[54], [55], [56]]
				117.070	[C₉H₉]⁺	[18,55]